The Annual PREGART Project Consortium meeting took place from August 5-6, 2024, at Haile Resort in Hawassa City, Ethiopia. The event brought together over 60 participants, including consortium members, government stakeholders, and representatives from the Ministry of Health, the Ethiopian Food and Drug Authority, and partner organizations. Attendees gathered to review the project's progress, share insights, and outline plans for the year ahead.
The meeting began with a welcoming address by Dr. Ayano Beraso, President of Hawassa University, followed by keynote speeches from representatives of the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Ministry of Health of Ethiopia. The speakers highlighted the crucial role of collaboration, innovation, and effective communication in achieving the objectives of the PREGART Project.
The opening session of the PREGART Project meeting provided a thorough overview, covering project progress, challenges encountered during the COVID-19 pandemic, and strategies adopted to overcoming them. The workshop served as a platform for participants to reflect on the accomplishments of the past year, exchange best practices, and identify areas for further improvement.
Subsequent closed sessions for consortium members from Ethiopia, Uganda, and Sweden focused on status of study participants recruitment and follow-up, data management and analysis methods, and preliminary findings. Four PhD students presented updates on their ongoing research followed by interactive discussions and guidance to sustain their momentum in their respective studies.
The workshop celebrated achievements and tackled project challenges, concluding with a renewed commitment to the project's goals and a focus on continuous improvement and collaborative success. The PREGART Project is dedicated to enhancing antiretroviral treatment outcomes for pregnant women and improving prevention of mother-to-child transmission (PMTCT) across Africa.
The PREGART Project remains dedicated to fostering collaboration, driving innovation, and advancing research to improve antiretroviral treatment outcomes for pregnant women and enhance prevention of mother-to-child transmission (PMTCT) outcomes across Africa.
The PREGART project is part of the EDCTP2 Programme supported by the European Union.
